GSK to pay $317K in EPA settlement; Cipla profits fall short; Amnal adding Northern Ireland jobs;

@FiercePharma: ICYMI: This week's issue of FiercePharmaMarketing. Want more? Subscribe here. | Follow @FiercePharma

@EricPFierce: ICYMI yesterday: Merck KGaA has to rely on AZ as its pharma sales contract in Q2. Article | Follow @EricPFierce

@CarlyHFierce: Sovaldi payer pushback hurting access for opioid treatment patients. Story | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) agreed to pay $317,550 and to manage its hazardous waste properly in a deal with the U.S. Environmental Protection agency over alleged violations at an R&D facility in Pennsylvania. Report

> India's Cipla posted lower-than-expected profits of 2.95 billion rupees ($48.6 million) because higher costs ate away at the bottom line. Report

> The pharma company Amnal Group plans to add 350 jobs in two divisions at its Northern Ireland headquarters. Report

> Hong Kong's customs department is scrutinizing the safety of Colgate's Total toothpaste, which contains the controversial chemical triclosan. Report

Medical Device News

@FierceMedDev: ICYMI: Here's yesterday's issue of FierceDrugDelivery. | Follow @FierceMedDev

@StacyALawrence: You're so fierce: A call for nominations of the top women in med tech. Editor's corner | Follow @StacyALawrence

@VarunSaxena2: Big VC scoop from my colleague : Sofinnova spinoff HealthQuest targets $110M, makes first investments. News | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: Medicated electrospun fabric offers alternative delivery method for HIV-preventing drugs. FierceDrugDelivery story | Follow @EmilyWFierce

> J&J freed from Stryker lawsuit, could face renewed battle with Medinol over stent patents. More

> Sofinnova spinoff HealthQuest targets $110M, makes first investments. Story

> California devicemaker rakes in $15M for innovative transcarotid stent system. Article

Biotech News

@FierceBiotech: Merck wins FDA nod for a weaker form of its embattled sleep drug. Article | Follow @FierceBiotech

@DamianFierce: ICYMI yesterday: $MRK's suvorexant will sell as Belsomra, but dosing issue will likely limit its market value. Article | Follow @DamianFierce

@EmilyMFierce: Science! What's Up With That: Why It's So Hard to Catch Your Own Typos. Wired story | Follow @EmilyMFierce

> InterMune buyout rumors resurface, with Roche, Sanofi on the short list. More

> Allergan bets up to $588M on Taris' bladder candidate. News

> Prefer a Swiss tax rate? Basilea chief says he's ready to parley. Story

> AstraZeneca squares off against Roche in blockbuster PhIII asthma showdown. Article

Vaccines News

> Sanofi's high-dose Fluzone beats standard-dose version in protecting seniors. More

> Researchers retract narcolepsy study linked to Glaxo's Pandemrix. Report

> Health Canada signs off on GSK's plans to improve its flu vaccine plant. More

> Pfizer's Prevnar gets $2B boost with CDC nod in older adults. Article

> Dendreon's debt plans could leave stockholders in the lurch. Story

Pharma Manufacturing News

> Shire takes over production of Buccolam after contractor fails. Article

> Amgen recalls Aranesp syringes contaminated with polyester. Report

> Indian regulator lays down new standards for its inspectors. More

> Baxter recalls another lot of saline solution as shortage persists. Story

> Canada says GSK flu vaccine plant is on track; the FDA remains mum. Item

> Wockhardt's run-ins with the FDA cost it most of its profits for a quarter. Article

And Finally... Bisphosphonate drugs for osteoporosis don't reduce the risk of breast cancer as previously thought, a study found. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.